More data should mean less risk. In nonclinical development, that's not always true. In this episode, we explore the concept of data hormesis — the inflection point where accumulating more data stops reducing uncertainty and starts creating it. If your team is running another study because the last one didn't give you the answer you needed, this episode is for you.

Key takeaways:

• Data hormesis is the point where more information stops helping and starts obscuring the path forward — just like a drug that's beneficial at low doses and toxic at high ones
• Early in development, data reduce uncertainty. Beyond a certain point, signals compete for attention rather than converging toward resolution
• When decisions aren't defined early, data accumulation quietly becomes a substitute for judgment rather than a tool to support it
• The patterns are recognizable: equivocal findings trigger rework instead of interpretation, borderline results lead to more studies without clarity on what would actually change
• Programs that move efficiently to IND aren't the ones with the most data — they're the ones that decided early which risks are acceptable and which questions are worth answering now
• Data don't create strategy. They make strategy visible.

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/02xUsV6K
• Work with Dessi: www.toxistrategy.com

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

"No major findings." Three words that instantly lower the blood pressure of every executive in the room — and sometimes, quietly derail a program. In this episode, we unpack why a clean toxicology study can still leave your IND dangerously exposed, what teams consistently get wrong when they see no major findings, and why the absence of a finding is never the end of interpretation — it's where interpretation has to begin.

Key takeaways:

• "No major findings" describes what was not observed — it is not an interpretation of what the study resolved
• A clean study still leaves critical questions open: how close was exposure to the clinical range? What assumptions are now baked in about escalation?
• Once "no major findings" enters the conversation, behavior changes — dose rationales harden, exposure assumptions stop being tested, follow-on studies are designed from reassurance instead of uncertainty
• The consequence doesn't show up in nonclinical — it shows up at IND when you're asked to justify decisions you thought were already made
• Strong programs use clean studies as an opportunity to do more thinking, not less — documenting assumptions, defining boundaries, and stating explicitly what would change the program's direction

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/02xUsV6K
• Work with Dessi: https://www.toxistrategy.com/

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.

"Our CRO has QA — we're covered." It's one of the most common phrases in biotech, and one of the most dangerous assumptions in nonclinical development. In this episode, we break down the critical difference between CRO QA and sponsor-side oversight, why GLP compliance and regulatory strategy are two completely different things, and what happens when nobody is doing the sponsor's job.

Key takeaways:

• CRO QA ensures the CRO complies with GLP — that's it. It does not ensure your study design supports your regulatory strategy
• When a protocol deviation occurs, CRO QA documents it perfectly — but nobody assesses whether it invalidates your NOAEL or affects your IND
• Big Pharma has five layers of oversight. Most biotechs have two and hope that's enough — the missing layer is sponsor-side QA
• Real-time study monitoring with a regulatory lens is what catches problems when you can still fix them, not six months later in the final report
• Most biotechs choose to do nothing by default — not because they've evaluated the risk, but because they don't know the gap exists

Links:

• Data Is Not Strategy on Amazon: https://a.co/d/02xUsV6K
• Work with Dessi: www.toxistrategy.com

The Nonclinical is hosted by Dessi McEntee, MS, DABT — board-certified toxicologist and Fractional Head of Toxicology. Subscribe to the newsletter on LinkedIn, take the course at nonclinical.academy, or work with Dessi at toxistrategy.com.